Modulation of NR1 receptor by CaMKIIα plays an important role in chronic itch development in mice.

Brain Res Bull

Department of Pain Management, The State Key Clinical Specialty in Pain Medicine, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, P.R. China. Electronic address:

Published: May 2020


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Intractable scratching is the characteristic of chronic itch, which represents a great challenge in clinical practice. However, the mechanism underlying chronic itch development is largely unknown. In the present study, we investigated the role of NMDA receptor in acute itch and in development of chronic itch. A mouse model was developed by painting DNFB to induce allergic contact dermatitis (ACD). We found that the expression of pNR1, which is a subunit of NMDA receptor, was significantly increased in the dorsal root ganglion in the DNFB model. The DNFB-evoked spontaneous scratching was blocked by the NMDA antagonist D-AP-5, the calcium-calmodulin-dependent protein kinase (CaMK) inhibitor KN-93, a CaMKIIα siRNA and the PKC inhibitor LY317615. Moreover, activation of PKC did not reverse the CaMKIIα knockdown-induced decrease in scratching, suggesting that PKC functions upstream of CaMKIIα. Thus, our study indicates that modulation of NR1 receptor by CaMKIIα plays an important role in the development of chronic itch.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brainresbull.2020.02.011DOI Listing

Publication Analysis

Top Keywords

chronic itch
20
itch development
12
modulation nr1
8
nr1 receptor
8
receptor camkiiα
8
camkiiα plays
8
plays role
8
nmda receptor
8
development chronic
8
itch
6

Similar Publications

Rationale: Extracorporeal membrane oxygenation (ECMO) is a life-support technology for refractory cardiac arrest, but the massive blood transfusions required during treatment significantly increase the risk of transfusion-related infections. Hepatitis E virus (HEV) - traditionally linked to fecal-oral transmission - is increasingly recognized as a transfusion-transmitted pathogen, especially in emergency settings where urgent blood product infusion is common and routine HEV screening in blood banks is often lacking. However, nursing strategies for managing acute HEV infection after ECMO remain poorly defined, highlighting the need to address this clinical gap.

View Article and Find Full Text PDF

Atopic dermatitis (AD) is a chronic dermatological disorder characterized by intense pruritus and eczematous lesions. Repeated topical application of 2,4-dinitrofluorobenzene (DNFB) in NC/Nga mice produces AD-like clinical symptoms that closely resemble human AD. N-Acetyl-L-Alanine (L-NAA), a derivative of L-Alanine, has unknown biological and physiological effects on cutaneous tissue.

View Article and Find Full Text PDF

Targeting PAR-2 in atopic dermatitis: Preclinical evaluation of the novel inhibitor E6795.

Biochem Biophys Res Commun

September 2025

Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan; A∗STAR Skin Research Labs (A∗SRL), Skin Research Institute of Singapore (SRIS), Singapore Immunology Network (SIgN), Agency for Science, Technology, and Research (A∗STAR), 8A Biomedical Grove, IMMUNOS Buildi

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by eczematous lesions, intense itching, and compromised skin barrier function. Despite the advent of new therapeutics, many individuals still face insufficient disease control, high costs, and relapse. Protease-activated receptor 2 (PAR-2), overexpressed in AD lesions, plays a central role in promoting inflammation, itch, and alterations in epidermal homeostasis.

View Article and Find Full Text PDF

Atopic dermatitis (AD) is a chronic inflammatory disease characterized by eczematous skin lesions, intense pruritus, skin pain, sleep disruption, and mental health disturbances. There remains a need for a therapeutic option that delivers durable efficacy, safety, and convenient dosing across the AD patient population. This review provides an overview of AD pathogenesis driven by T-cell imbalance and describes a novel therapeutic option targeting the OX40 receptor, a costimulatory molecule expressed specifically on activated T cells.

View Article and Find Full Text PDF

Background: Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by complex interactions among Staphylococcus aureus colonization and immunologic, genetic, and environmental (SAIGE) triggers. Currently, no single therapy comprehensively addresses all triggers and the full spectrum of AD manifestations, highlighting an unmet need for therapies that simultaneously target all components of the disease continuum.

Methods: An expert panel conducted a structured literature review and developed consensus statements during a meeting in March 2025.

View Article and Find Full Text PDF